NAIROBI, Kenya, June 18 – Cancer Care Kenya, which operates the HCG Cancer Centre, increased its revenue by 71 percent to Sh1.01 billion in the year ended March 31, 2026, driven by higher patient numbers and increased demand for cancer treatment services.
Financial disclosures by parent company HealthCare Global Enterprises Ltd show the Kenyan business generated about Sh1.01 billion in 2026, up from Sh593 million the previous year.
The Nairobi operation contributed about five percent of HCG Group’s total revenue during the period, according to the company’s regional performance update.
Growth remained strong in the final quarter of the financial year, with revenue rising 39 percent to Sh269 million from Sh193 million in the corresponding quarter a year earlier.
The company attributed the improvement to stronger operating momentum, increased patient inflows and a broader mix of cancer treatment services offered at the facility.
Cancer Care Kenya, which offers oncology services from diagnosis to chemotherapy, radiotherapy, and other advanced cancer treatments, is part of HCG’s international healthcare portfolio, which also includes the Milann fertility business in India.
HCG has announced plans to divest the Milann business, with the transaction expected to be completed in the first quarter of 2027.
